Cellular Reprogramming as a Strategy for Radical Rejuvenation

Background. June 2026 marks the first-ever FDA clearance of a clinical trial for partial cellular reprogramming in humans — Life Biosciences’ ER-100 (OSK factors) for optic neuropathies. In parallel, longevity-biotech investments have surpassed $10 billion, and media discourse increasingly operates with concepts such as “rebooting the cellular clock” and “radical rejuvenation.” However, a systematic analysis of the evidence base reveals a significant gap between laboratory achievements and clinical reality. Objective. To conduct a balanced critical analysis of the fundamental and translational limitations of partial cellular reprogramming, with emphasis on: (1) the p53-suppression dilemma and oncogenicity, including a strict distinction between data from full versus partial reprogramming(definition); (2) the validity of epigenetic aging biomarkers in light of the latest clinical clocks, LinAge2 and GrimAge2; (3) technological barriers to systemic delivery; (4) evolutionary constraints and natural counterexamples of rejuvenation; (5) alternative reprogramming platforms, including chemical reprogramming. Methods. Systematic search of PubMed/MEDLINE, Scopus, Web of Science, bioRxiv, and arXiv for the period 2006–2026. A total of 135 publications were selected for full-text analysis. A meta-analysis of 9 studies on p53 suppression in full reprogramming (iPSC) models was conducted, with explicit caveats regarding extrapolation to partial reprogramming in vivo. Epigenetic clock(definition) analysis was performed on 15 independent cohorts (n = 10,615). An additional 18 preprints from 2025–2026 were analyzed. Results. (1) Meta-analysis of 9 full-reprogramming (iPSC) studies in vitro shows that p53 suppression increases reprogramming efficiency by a pooled 27.8-fold (95% CI: 15.3–50.6, p < 0.001). However, these data derive from models of full reprogramming with continuous OSKM expression (14–28 days) and cannot be directly extrapolated to transient partial reprogramming in vivo (2–7 days of expression), for which systematic p53-activation data are absent. (2) Modern clinical clocks (LinAge2, GrimAge2) achieve AUC > 0.80 for 20-year mortality prediction, representing significant progress over first-generation chronological clocks; however, no clock has been validated as a surrogate endpoint specifically for OSK interventions. (3) Analysis of 23 AAV delivery studies shows that the 4 fatal outcomes recorded in the AUDENES trials (2020–2023) were associated with high AAV9 doses in children under 2 years of age with pre-existing neutralizing antibodies — a context substantially different from low-dose local ER-100 administration in adults. (4) Contrary to the thesis of “fundamental impossibility of rejuvenation,” nature provides multiply confirmed examples of physiological rejuvenation: Turritopsis dohrnii (immortal jellyfish), Mnemiopsis leidyi (ctenophore with life-cycle reversibility), reversion of foragers to nurses in honeybees with full physiological rejuvenation [Aisin & Lidsky, 2025]. (5) Chemical partial reprogramming (7c and 2c cocktails) — an alternative platform that requires neither AAV nor provokes p53 hyperactivation — has demonstrated, for the first time, lifespan extension in C. elegans by >42% [Chen et al., EMBO Mol Med, 2025]. Conclusion. Partial cellular reprogramming remains a promising but experimental technology. The gap between tissue-specific gene therapy (ER-100 for optic neuropathies) and hypothetical systemic rejuvenation remains substantial; however, emerging platforms — chemical reprogramming, LNP-mRNA, and mosaic approaches — may close this gap faster than previously assumed. A scenario analysis (optimistic, baseline, pessimistic) is presented, with justifications for each scenario.